Related Experiment Videos

[Treatment of DIC associated with myelogenous leukemia]

Yoichi Sakata1

  • 1Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 29, 2009
PubMed

Insights

Disseminated intravascular coagulation (DIC) in myelogenous leukemia requires anticoagulant therapy alongside anti-tumor drugs for effective treatment. Recombinant thrombomodulin and natural anticoagulant pathways improve patient outcomes by regulating coagulation and preventing organ damage.

Area of Science:

  • Hematology
  • Oncology
  • Pathophysiology

Context:

  • Myelogenous leukemia is increasingly curable.
  • Disseminated intravascular coagulation (DIC) is a complication of myelogenous leukemia.
  • Current treatment paradigms for DIC in leukemia may be insufficient.

Purpose:

  • To highlight the pathophysiology of 3 DIC types.
  • To advocate for anticoagulant therapy in DIC associated with myelogenous leukemia before hematological remission.
  • To introduce recombinant thrombomodulin as a novel treatment for DIC.

Summary:

  • Anti-tumor drugs and platelet transfusions alone may not be sufficient for treating DIC in myelogenous leukemia.
  • Anticoagulant therapy is crucial to prevent bleeding and ischemic organ damage prior to achieving hematological remission.
  • Recombinant thrombomodulin activates the protein C pathway, regulating coagulation.
  • Combining antithrombin and protein C pathways offers a more effective treatment strategy for DIC.

Impact:

  • Improved management of DIC in myelogenous leukemia patients.
  • Reduced risk of bleeding death and ischemic organ damage.
  • Enhanced patient outcomes through comprehensive coagulation regulation.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...